Mannaerts B

ORCID: 0000-0001-9127-8013 · 9 papers in corpus
2023
Ganirelix and the prevention of premature luteinizing hormone surges.
F&S reports ·doi:10.1016/j.xfre.2023.02.009

Ganirelix is a gonadotropin-releasing hormone (GnRH) antagonist with high antagonistic activity that blocks the GnRH receptor by competitive binding. A daily dose of 0.25 mg of ganirelix was sel5ected after a phase II study because it was t…

2023
Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-023-01090-w

PurposeTo explore the efficacy and safety of individualized follitropin delta dosing, based on serum anti-Müllerian hormone (AMH) concentration and bodyweight, in a long gonadotropin-releasing hormone (GnRH) agonist protocol.MethodsClinical…

2022
A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deac061

Study questionDoes addition of choriogonadotropin beta (recombinant CG beta) to follitropin delta increase the number of good-quality blastocysts following ovarian stimulation in a long GnRH agonist protocol?Summary answerAt the doses inves…

2022
Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Reproductive biology and endocrinology : RB&E ·doi:10.1186/s12958-022-01016-y

BackgroundTo compare the efficacy and safety of follitropin delta in its individualized fixed-dose regimen with follitropin alfa in a conventional adjustable dosing regimen in Chinese women.  METHODS: This was a subgroup analysis of the ran…

2022
Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosing.
Frontiers in endocrinology ·doi:10.3389/fendo.2022.1004596

BackgroundChoriogonadotropin (CG) beta (FE 999302), a novel recombinant human (h)CG produced by a human cell line, has a longer half-life and higher potency than CG alfa produced by a Chinese hamster ovary cell line. hCG augments steroid pr…

2021
A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deab155

Study questionIs ovarian stimulation with follitropin delta in its individualised fixed-dose regimen at least as efficacious as follitropin alfa in a conventional dosing regimen in Asian population?Summary answerOvarian stimulation with ind…

2021
Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta.
Journal of assisted reproduction and genetics ·doi:10.1007/s10815-021-02271-5

PurposeTo describe the pregnancy and neonatal outcomes using fresh and vitrified/warmed blastocysts obtained from ovarian stimulation with follitropin delta in controlled trials versus follitropin alfa.MethodsThis investigation evaluated th…

2014
A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
Human reproduction (Oxford, England) ·doi:10.1093/humrep/deu030
2013
Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation.
Reproductive biology and endocrinology : RB&E ·doi:10.1186/1477-7827-11-90

BackgroundWe sought to evaluate the incidence and clinical impact of luteinizing hormone (LH) rises prior to and during gonadotropin-releasing hormone (GnRH) antagonist treatment started on day 5 or 6 of ovarian stimulation with recombinant…